# An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands

> **NCT02891551** · — · COMPLETED · sponsor: **Celgene** · enrollment: 209 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myeloid, Acute

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02891551
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-01
- **Primary completion:** 2016-06-30
- **Final completion:** 2018-12-30
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02891551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02891551, "An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02891551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*